The impact of hepatitis B virus infection and vaccination on the development of non-Hodgkin lymphoma

C. E. Huang, Y. H. Yang, Y. Y. Chen, J. J. Chang, K. J. Chen, C. H. Lu, K. D. Lee, P. C. Chen, C. C. Chen

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Hepatitis B virus (HBV) infection has been documented as a risk factor for non-Hodgkin lymphoma (NHL). However, there are few large cohort studies, and there is no report about the impact of HBV vaccination. We conducted this study to evaluate these issues. We used the nationwide cohort of the Taiwan National Health Insurance Research Database for 1997–2013. We compared the incidence and the risk of developing NHL and CD20+ aggressive lymphoma between HBV and non-HBV cohorts. The hazard ratios (HRs) were computed using Cox proportional hazards models. We matched these two large cohorts to reconfirm the data. We also compared the incidence of NHL between cohorts born before and after the inception of universal HBV vaccination. We found that HBV infection increased the risk for developing NHL and CD20+ aggressive lymphoma, with HRs of 4.14 and 5.52, with a higher incidence of 17.07 and 13.9 per 100 000 person-years, respectively, compared to the non-HBV cohort. The incidence of NHL in the cohort born in the era before universal HBV vaccination was higher with 1.85 per 100 000 person-years compared to 0.74 in the cohort born later aged younger than 20. Our study confirms that HBV confers a greater risk for developing NHL, especially CD20+ aggressive lymphoma. The impact of HBV vaccination is protective against lymphoma development in the teenagers in an endemic area, but longer follow-up is needed for older age.

Original languageEnglish
Pages (from-to)885-894
Number of pages10
JournalJournal of Viral Hepatitis
Volume24
Issue number10
DOIs
Publication statusPublished - Oct 1 2017
Externally publishedYes

Fingerprint

Virus Diseases
Hepatitis B virus
Non-Hodgkin's Lymphoma
Vaccination
Lymphoma
Cercopithecine Herpesvirus 1
Incidence
National Health Programs
Taiwan
Proportional Hazards Models
Cohort Studies
Databases
Research

Keywords

  • diffuse large B-cell lymphoma
  • hepatitis B
  • non-Hodgkin lymphoma
  • risk
  • vaccination

ASJC Scopus subject areas

  • Hepatology
  • Infectious Diseases
  • Virology

Cite this

Huang, C. E., Yang, Y. H., Chen, Y. Y., Chang, J. J., Chen, K. J., Lu, C. H., ... Chen, C. C. (2017). The impact of hepatitis B virus infection and vaccination on the development of non-Hodgkin lymphoma. Journal of Viral Hepatitis, 24(10), 885-894. https://doi.org/10.1111/jvh.12713

The impact of hepatitis B virus infection and vaccination on the development of non-Hodgkin lymphoma. / Huang, C. E.; Yang, Y. H.; Chen, Y. Y.; Chang, J. J.; Chen, K. J.; Lu, C. H.; Lee, K. D.; Chen, P. C.; Chen, C. C.

In: Journal of Viral Hepatitis, Vol. 24, No. 10, 01.10.2017, p. 885-894.

Research output: Contribution to journalArticle

Huang, CE, Yang, YH, Chen, YY, Chang, JJ, Chen, KJ, Lu, CH, Lee, KD, Chen, PC & Chen, CC 2017, 'The impact of hepatitis B virus infection and vaccination on the development of non-Hodgkin lymphoma', Journal of Viral Hepatitis, vol. 24, no. 10, pp. 885-894. https://doi.org/10.1111/jvh.12713
Huang, C. E. ; Yang, Y. H. ; Chen, Y. Y. ; Chang, J. J. ; Chen, K. J. ; Lu, C. H. ; Lee, K. D. ; Chen, P. C. ; Chen, C. C. / The impact of hepatitis B virus infection and vaccination on the development of non-Hodgkin lymphoma. In: Journal of Viral Hepatitis. 2017 ; Vol. 24, No. 10. pp. 885-894.
@article{9a5afb32600a4fd88568aeb969eaaabb,
title = "The impact of hepatitis B virus infection and vaccination on the development of non-Hodgkin lymphoma",
abstract = "Hepatitis B virus (HBV) infection has been documented as a risk factor for non-Hodgkin lymphoma (NHL). However, there are few large cohort studies, and there is no report about the impact of HBV vaccination. We conducted this study to evaluate these issues. We used the nationwide cohort of the Taiwan National Health Insurance Research Database for 1997–2013. We compared the incidence and the risk of developing NHL and CD20+ aggressive lymphoma between HBV and non-HBV cohorts. The hazard ratios (HRs) were computed using Cox proportional hazards models. We matched these two large cohorts to reconfirm the data. We also compared the incidence of NHL between cohorts born before and after the inception of universal HBV vaccination. We found that HBV infection increased the risk for developing NHL and CD20+ aggressive lymphoma, with HRs of 4.14 and 5.52, with a higher incidence of 17.07 and 13.9 per 100 000 person-years, respectively, compared to the non-HBV cohort. The incidence of NHL in the cohort born in the era before universal HBV vaccination was higher with 1.85 per 100 000 person-years compared to 0.74 in the cohort born later aged younger than 20. Our study confirms that HBV confers a greater risk for developing NHL, especially CD20+ aggressive lymphoma. The impact of HBV vaccination is protective against lymphoma development in the teenagers in an endemic area, but longer follow-up is needed for older age.",
keywords = "diffuse large B-cell lymphoma, hepatitis B, non-Hodgkin lymphoma, risk, vaccination",
author = "Huang, {C. E.} and Yang, {Y. H.} and Chen, {Y. Y.} and Chang, {J. J.} and Chen, {K. J.} and Lu, {C. H.} and Lee, {K. D.} and Chen, {P. C.} and Chen, {C. C.}",
year = "2017",
month = "10",
day = "1",
doi = "10.1111/jvh.12713",
language = "English",
volume = "24",
pages = "885--894",
journal = "Journal of Viral Hepatitis",
issn = "1352-0504",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - The impact of hepatitis B virus infection and vaccination on the development of non-Hodgkin lymphoma

AU - Huang, C. E.

AU - Yang, Y. H.

AU - Chen, Y. Y.

AU - Chang, J. J.

AU - Chen, K. J.

AU - Lu, C. H.

AU - Lee, K. D.

AU - Chen, P. C.

AU - Chen, C. C.

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Hepatitis B virus (HBV) infection has been documented as a risk factor for non-Hodgkin lymphoma (NHL). However, there are few large cohort studies, and there is no report about the impact of HBV vaccination. We conducted this study to evaluate these issues. We used the nationwide cohort of the Taiwan National Health Insurance Research Database for 1997–2013. We compared the incidence and the risk of developing NHL and CD20+ aggressive lymphoma between HBV and non-HBV cohorts. The hazard ratios (HRs) were computed using Cox proportional hazards models. We matched these two large cohorts to reconfirm the data. We also compared the incidence of NHL between cohorts born before and after the inception of universal HBV vaccination. We found that HBV infection increased the risk for developing NHL and CD20+ aggressive lymphoma, with HRs of 4.14 and 5.52, with a higher incidence of 17.07 and 13.9 per 100 000 person-years, respectively, compared to the non-HBV cohort. The incidence of NHL in the cohort born in the era before universal HBV vaccination was higher with 1.85 per 100 000 person-years compared to 0.74 in the cohort born later aged younger than 20. Our study confirms that HBV confers a greater risk for developing NHL, especially CD20+ aggressive lymphoma. The impact of HBV vaccination is protective against lymphoma development in the teenagers in an endemic area, but longer follow-up is needed for older age.

AB - Hepatitis B virus (HBV) infection has been documented as a risk factor for non-Hodgkin lymphoma (NHL). However, there are few large cohort studies, and there is no report about the impact of HBV vaccination. We conducted this study to evaluate these issues. We used the nationwide cohort of the Taiwan National Health Insurance Research Database for 1997–2013. We compared the incidence and the risk of developing NHL and CD20+ aggressive lymphoma between HBV and non-HBV cohorts. The hazard ratios (HRs) were computed using Cox proportional hazards models. We matched these two large cohorts to reconfirm the data. We also compared the incidence of NHL between cohorts born before and after the inception of universal HBV vaccination. We found that HBV infection increased the risk for developing NHL and CD20+ aggressive lymphoma, with HRs of 4.14 and 5.52, with a higher incidence of 17.07 and 13.9 per 100 000 person-years, respectively, compared to the non-HBV cohort. The incidence of NHL in the cohort born in the era before universal HBV vaccination was higher with 1.85 per 100 000 person-years compared to 0.74 in the cohort born later aged younger than 20. Our study confirms that HBV confers a greater risk for developing NHL, especially CD20+ aggressive lymphoma. The impact of HBV vaccination is protective against lymphoma development in the teenagers in an endemic area, but longer follow-up is needed for older age.

KW - diffuse large B-cell lymphoma

KW - hepatitis B

KW - non-Hodgkin lymphoma

KW - risk

KW - vaccination

UR - http://www.scopus.com/inward/record.url?scp=85019630816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019630816&partnerID=8YFLogxK

U2 - 10.1111/jvh.12713

DO - 10.1111/jvh.12713

M3 - Article

AN - SCOPUS:85019630816

VL - 24

SP - 885

EP - 894

JO - Journal of Viral Hepatitis

JF - Journal of Viral Hepatitis

SN - 1352-0504

IS - 10

ER -